Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization

Table 1 Efficacy of transcatheter arterial chemoembolization in different types of hepatocellular carcinoma, n (%)

Group	n	CR (%)	PR (%)	SD (%)	PD (%)
Massive type	71	0	17 (23.94)	41 (57.75)	13 (18.31)
Nodular type	80	0	13 (16.25)	34 (42.50)	33 (41.25)
Diffuse type	11	0	0	7 (63.64)	4 (36.36)

CR: Complete remission; PR: Partial remission; SD: Stable disease; PD: Disease progression.

Table 2 Comparison of baseline data between hepatocellular carcinoma group and healthy group

Group	Number of cases	Age	BMI
Cancer group	162	51.31 ± 4.21	26.04 ± 2.54
Health group	162	52.30 ± 5.28	25.73 ± 2.55
t	1.87		0.31
P value	0.06		0.27

BMI: Body mass index.

Table 3 Remission and recurrence of hepatic cancer patients undergoing hepatic artery embolization chemotherapy (transcatheter arterial chemoembolization)

Group	Remission	Relapse	χ2	P value
Classification of HCC			9.44	< 0.05
Massive type, n = 71	58	13
Nodular type, n = 80	47	33
Diffuse type, n = 11	7	4
Preoperative staging			30.59	< 0.05
II stage, n = 97	83	14
III stage, n = 65	29	36
Child-Pugh			60.08	< 0.05
Child A, n = 42	34	8
Child B, n = 88	74	14
Child C, n = 32	4	28
AFP level			0.87	> 0.05
> 400 ng/mL, n = 124	86	38
20-400 ng/mL, n = 10	8	2
< 20 ng/mL, n = 28	18	10

HCC: Hepatocellular carcinoma; AFP: Alpha fetoprotein.

Table 4 Comparison of serum glypican-3 and miR-1271 levels in patients with hepatocellular carcinoma

Group	Number of cases	Glypican-3	t	P value	miR-1271	t	P value
Group 1			7.41	< 0.05		18.06	< 0.05
Health group	162	0.74 ± 0.29			5.48 ± 1.79
Cancer group	162	8.87 ± 3.73			1.25 ± 0.68
Group 2			18.06	< 0.05		18.06	< 0.05
Before treatment	162	8.87 ± 3.73			1.25 ± 0.68
After treatment	162	2.46 ± 1.69			4.64 ± 2.13
Group 3			7.6	< 0.05		4.17	< 0.05
Remission group	112	6.79 ± 5.32			4.96 ± 2.28
Recurrent group	50	8.74 ± 2.40			3.41 ± 1.96

Table 5 Comparison of sensitivity, specificity, and accuracy of miR-1271 and glypican-3 alone and jointly for detection of hepatocellular carcinoma (%)

Items	Sensitivity	Specificity	Accuracy	RR (95%CI)
GPC3	68.9	86.0	75.3	0.926 (0.561-1.471)
miR-1271	76.0	72.8	76.5	0.925 (0.374-1.482)
GPC3 + miR-1271	94.7	65.0	80.3	0.931 (0.537-1.312)

GPC3: Glypican-3.